Angiodynamics (ANGO) Liabilities and Shareholders Equity (2016 - 2026)
Angiodynamics' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $260.7 million for Q1 2026.
- For Q1 2026, Liabilities and Shareholders Equity fell 8.67% year-over-year to $260.7 million; the TTM value through Feb 2026 reached $1.1 billion, down 9.44%, while the annual FY2025 figure was $280.1 million, 11.81% down from the prior year.
- Liabilities and Shareholders Equity reached $260.7 million in Q1 2026 per ANGO's latest filing, down from $269.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $558.2 million in Q4 2022 to a low of $260.7 million in Q1 2026.
- Average Liabilities and Shareholders Equity over 5 years is $404.1 million, with a median of $324.8 million recorded in 2024.
- Peak YoY movement for Liabilities and Shareholders Equity: rose 0.74% in 2022, then plummeted 41.65% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $558.2 million in 2022, then fell by 10.5% to $499.6 million in 2023, then tumbled by 41.65% to $291.6 million in 2024, then decreased by 7.5% to $269.7 million in 2025, then decreased by 3.34% to $260.7 million in 2026.
- Per Business Quant, the three most recent readings for ANGO's Liabilities and Shareholders Equity are $260.7 million (Q1 2026), $269.7 million (Q4 2025), and $265.6 million (Q3 2025).